Article

Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline<i>APOBEC3B</i>deletion: results of the phase II AUROR study

2024-08-07

Abstract excerpt

<h4>Background</h4> A common germline deletion polymorphism in the APOBEC3B gene increases the rate of somatic hypermutation in breast cancer, which in turn is associated with greater neoantigen burden and immune activation. This phase II study evaluated the impact of the APOBEC3B deletion polymorphism on the response to pembrolizumab monotherapy in metastatic HER2-negative breast cancer patients. <h4>Patients and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f72e3a59-f18e-5fec-8129-2465de32529e
DOI: 10.1101/2024.08.07.24311537

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline<i>APOBEC3B</i>deletion: results of the phase II AUROR studyDOI 10.1101/2024.08.07.24311537Read

Germline <i>APOBEC3B</i> deletion in Asian women increases somatic hypermutation in breast cancer that is associated with Her2 subtype, <i>PIK3CA</i> mutations, immune activation, and increased survivalSemantic proximity Read

Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activationSemantic proximity Read

Prevalence and mutational determinants of high tumor mutation burden in breast cancerSemantic proximity Read

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.Semantic proximity Read

Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.Semantic proximity Read

APOBEC3 mutagenesis drives therapy resistance in breast cancerSemantic proximity Read

Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.Semantic proximity Read

Prevalence and mutational determinants of high tumor mutation burden in breast cancer.Semantic proximity Read

PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer PatientsSemantic proximity Read

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancerSemantic proximity Read

Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world StudySemantic proximity Read

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read